益佰制药
(600594)
| 流通市值:24.32亿 | | | 总市值:24.32亿 |
| 流通股本:7.84亿 | | | 总股本:7.84亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 989,980,001.03 | 689,387,704.62 | 358,837,040.95 | 1,862,920,853.13 |
| 营业总成本 | 1,110,706,131.69 | 742,482,846.67 | 374,652,779.96 | 2,001,366,895.95 |
| 其他经营收益 | | | | |
| 营业利润 | -142,137,191.98 | -74,186,475.64 | -21,904,407.07 | -303,982,173.75 |
| 利润总额 | -141,435,110.41 | -73,072,664.02 | -20,875,480.6 | -311,748,335.7 |
| 净利润 | -148,237,463.8 | -78,460,579.89 | -28,963,288.04 | -335,341,885.11 |
| 每股收益 | | | | |
| 其他综合收益 | -5,227.4 | 7,181.75 | - | -164,440.9 |
| 综合收益总额 | -148,242,691.2 | -78,453,398.14 | -28,963,288.04 | -335,506,326.01 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 1,263,583,964.28 | 1,345,071,697.57 | 1,443,079,324.15 | 1,447,717,750.36 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,896,650,446.66 | 1,921,889,296.68 | 1,955,146,882.67 | 1,994,117,912.4 |
| 资产总计 | 3,160,234,410.94 | 3,266,960,994.25 | 3,398,226,206.82 | 3,441,835,662.76 |
| 流动负债: | | | | |
| 流动负债合计 | 818,156,158.48 | 791,828,999.24 | 847,950,870.93 | 908,875,452.96 |
| 非流动负债: | | | | |
| 非流动负债合计 | 225,716,968.22 | 282,981,417.71 | 308,634,412.64 | 262,356,234.36 |
| 负债合计 | 1,043,873,126.7 | 1,074,810,416.95 | 1,156,585,283.57 | 1,171,231,687.32 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,036,531,155.15 | 2,107,456,243.01 | 2,158,262,207.32 | 2,187,786,874.36 |
| 股东权益合计 | 2,116,361,284.24 | 2,192,150,577.3 | 2,241,640,923.25 | 2,270,603,975.44 |
| 负债和股东权益合计 | 3,160,234,410.94 | 3,266,960,994.25 | 3,398,226,206.82 | 3,441,835,662.76 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,199,051,713.36 | 846,173,803.66 | 447,069,789.96 | 2,244,956,178.86 |
| 经营活动现金流出小计 | 1,118,684,198.57 | 782,032,289.31 | 401,891,726.59 | 1,988,250,966.52 |
| 经营活动产生的现金流量净额 | 80,367,514.79 | 64,141,514.35 | 45,178,063.37 | 256,705,212.34 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 21,169,427.3 | 896,325.59 | 817,934.59 | 6,988,631.89 |
| 投资活动现金流出小计 | 58,560,114.73 | 33,612,774.01 | 7,595,763.13 | 34,992,693.77 |
| 投资活动产生的现金流量净额 | -37,390,687.43 | -32,716,448.42 | -6,777,828.54 | -28,004,061.88 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 430,000,000 | 380,000,000 | 255,000,000 | 515,999,999.5 |
| 筹资活动现金流出小计 | 517,403,189.16 | 428,311,862.72 | 250,627,961.3 | 818,566,887.27 |
| 筹资活动产生的现金流量净额 | -87,403,189.16 | -48,311,862.72 | 4,372,038.7 | -302,566,887.77 |
| 汇率变动对现金及现金等价物的影响 | -17,355.41 | -13,286.08 | -7,856.67 | -8,941.59 |
| 现金及现金等价物净增加额 | -44,443,717.21 | -16,900,082.87 | 42,764,416.86 | -73,874,678.9 |
| 期末现金及现金等价物余额 | 400,688,913.76 | 428,232,548.1 | 487,897,047.83 | 445,132,630.97 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -16,900,082.87 | - | -73,874,678.9 |